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Abstract
Macrophage inhibitory cytokine-1 (MIC-1/GDF15) modulates food intake and body weight under physiological and
pathological conditions by acting on the hypothalamus and brainstem. When overexpressed in disease, such as in advanced
cancer, elevated serum MIC-1/GDF15 levels lead to an anorexia/cachexia syndrome. To gain a better understanding of its
actions in the brainstem we studied MIC-1/GDF15 induced neuronal activation identified by induction of Fos protein.
Intraperitoneal injection of human MIC-1/GDF15 in mice activated brainstem neurons in the area postrema (AP) and the
medial (m) portion of the nucleus of the solitary tract (NTS), which did not stain with tyrosine hydroxylase (TH). To
determine the importance of these brainstem nuclei in the anorexigenic effect of MIC-1/GDF15, we ablated the AP alone or
the AP and the NTS. The latter combined lesion completely reversed the anorexigenic effects of MIC-1/GDF15. Altogether,
this study identified neurons in the AP and/or NTS, as being critical for the regulation of food intake and body weight by
MIC-1/GDF15.
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Introduction
MIC-1/GDF15 is a divergent member of the transforming
growth factor-beta (TGFb) superfamily [1], also known by a
number of other names including growth differentiation factor 15
(GDF15) and non-steroidal anti-inflammatory drugs activated
gene 1 (NAG-1). It circulates in the blood of normal individuals
with a concentration range of about 150 to 1150 pg per ml [2,3],
however these levels rise in disease states. MIC-1/GDF15 is a
stress response cytokine whose expression is further induced by
processes such as inflammation, injury and malignancy [4], which
also increase its serum levels [5–7]. Consequently, its circulating
concentration represents a potential tool for the diagnosis and
management of diseases such as premalignant colonic polyps,
cancers, and cardiovascular diseases [3,8–11]. Additionally, serum
levels of MIC-1/GDF15 independently predict all cause mortality
and cognitive decline in aging populations [12,13].
In some disease states, especially in late stage cancer, chronic
renal failure and severe congestive heart failure, MIC-1/GDF15
serum levels frequently rise to 10,000 to 20,000 pg per ml and
occasionally to much higher levels [5,14,15]. Even moderate
elevation in MIC-1/GDF15 serum levels decreased food intake in
experimental animals, and prolonged elevation leads to cachexia
[16]. High MIC-1/GDF15 serum levels may cause cancer
anorexia/cachexia syndrome [17,18], a frequently observed
complication of advanced cancer, which causes significant
morbidity, predominantly by limiting therapy and accelerating
demise.
In addition to inducing anorexia in disease, recent data
suggested that MIC-1/GDF15 might also play a role in the
physiological regulation of appetite, body weight and fat
mass [19,20]. MIC-1/GDF15 germline gene knockout mice
(MIC-12/2) weighed more than their syngeneic controls, with
females having a greater increase in weight than males. MIC-12/2
mice of both sexes had an increased white fat mass, dominantly
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localised to visceral abdominal compartments. Female MIC-12/2
mice also ate more and had reduced basal energy expenditure
compared to syngenic controls, while male MIC-12/2 mice had a
milder phenotype. However, when male MIC-12/2 mice were
infused with sufficient recombinant human MIC-1/GDF15
(hMIC-1/GDF15) to raise their serum levels to the middle of
the normal human circulating range, their body weight and food
intake returned to the wild type level [19]. Consequently, It
appears likely that the anorexia/cachexia associated with marked
elevation of serum levels of MIC-1/GDF15, are due to the
subversion of a physiological pathway for appetite regulation.
MIC-1/GDF15 is thought to exert its anorexigenic effects via
direct actions on the central nervous system. Systemic adminis-
tration has been associated with activation of neurons in the
arcuate nucleus of the hypothalamus (Arc), the paraventricular
nucleus of the hypothalamus (PVN) and in the area postrema (AP)
of the brainstem [16]. In the Arc, where we have explored its
effects in more detail, systemically administered hMIC-1/GDF15
induced anorexigenic proopiomelanocortin (POMC), while down
regulating orexigenic neuropeptide Y (NPY) expression [16].
Further, viral-mediated MIC-1/GDF15 overexpression in the
mediobasal hypothalamic nucleus caused profound anorexia and
weight loss [16].
Like neurons in the Arc, brainstem neurons, especially in the AP
and nucleus of the solitary tract (NTS) also play a key role in
regulation of energy homeostasis [21]. Neurons of the AP and
NTS can be activated by direct vagal afferent inputs from the
gastrointestinal and other thoracic and abdominal viscera. In
addition to synaptic inputs, blood-borne factors including circu-
lating satiety hormones such as amylin, peptide YY (PYY) and
glucagon-like peptide-1 (GLP-1) can also selectively alter neural
activity in the AP and NTS. Here, they can enter the brain
through the fenestrated capillaries in the AP [22,23] and portions
of caudal medial NTS [24,25]. Additionally some molecules,
including leptin, can be actively transported across the blood brain
barrier (BBB) [26,27]. Lastly, tanycytes found in both AP and
NTS can also transport substances between blood and CSF [25].
Irrespective of how they are activated, neurons in the AP and
NTS can transmit signals widely. AP and NTS neurons are
densely and reciprocally interconnected and independently both
have extensive reciprocal neuronal connections with the hypo-
thalamus. These interconnections play an important role in
translating signals from or to hypothalamic regions [28–30]. There
are two major neuronal subtypes in the NTS: catecholamine
(norepinephrine/epinephrine) containing neurons, which are
commonly identified by the presence of its key regulator tyrosine
hydroxylase (TH) and non-catecholaminergic neurons. These are
composed of multiple subsets, each being identified by different,
sometimes overlapping, markers such as glucagon like peptide-1
(GLP-1), POMC, cocaine and amphetamine regulated transcript
(CART) or neurotensin [31–33]. Although both groups have been
implicated in mediating anorectic effects, the actions of the
catecholaminergic neurons in the NTS have been best character-
ized. For example, both cholecystokinin-8 (CCK-8) and leptin are
known to activate catecholamine neurons in the A2/C2 region of
the caudal medial NTS that project to the PVN oxytocin neurons
[34,35]. While non-catecholaminergic neurons within the NTS
also play important roles in energy homeostasis [21], their
functions are less well defined.
Neurons in the brainstem and especially in the AP and NTS
play an important role in regulating energy homeostasis and are
activated by MIC-1/GDF15 [16]. In this publication we focus our
studies on characterizing which of these AP/NTS regions and
neuronal subtypes are essential for the anorexigenic actions of
disease-associated concentrations of MIC-1/GDF15.
Methods
Animals
All experiments were conducted in accordance with relevant
guidelines and regulations with the oversight and approval of the
Garvan/St Vincent’s Animal Ethics Committee. Male C57BL/6
mice aged of 10–12 weeks were used, except where otherwise
stated. All mice were housed under controlled temperature (22uC)
with a 12:12 hr light-dark cycle (lights on at 07:00 hr) and had ad
libitum access to a standard chow and water.
Reagent and materials
Recombinant human MIC-1/GDF15 was expressed in Pichia
pastoris and purified in house, in a 3-step process as previously
described [36] [37]. Purified protein batches were tested and
found to be free of endotoxin. Rabbit-anti-Fos antibody was
generated and validated as previously described [38] and sheep-
anti-tyrosine hydroxylase (AB1542) were purchased from Milli-
pore (Merck KGaA, Darmstadt, Germany). DyLightTM488-
donkey-anti-rabbit IgG (711-475-152), and cy3-donkey-anti-
sheep-IgG (713-165-287) were all purchased from Jackson
ImmunoResearch (PA, USA).
ICV administration of hMIC-1/GDF15
Mice, 11–13 weeks of age, with average weights between 25–
30 g were anesthetized by intraperitoneal (IP) injection of
ketamine-xylazine mixture (80 mg/kg, 50 mg/kg, respectively).
The head was fixed to a stereotaxic platform (Model 900, KOPF
instruments, Tujunga, CA) and a guide cannula (C315GS-4,
Plastic One Inc., Roanoke, VA) was inserted through a burr hole
into the right lateral cerebral ventricle, using the stereotaxic
coordinates: 20.34 mm posterior from bregma; 1.0 mm lateral
from bregma and depth at 2.4 mm from the skull [39]. The
cannula was fixed to the skull with stainless steel screws and
surgical glue (Cerebond, Plastics One Inc., Roanoke, VA). The
cannula was capped (C315IDS-2, Plastics One Inc., Roanoke, VA)
to avoid contamination and the mice were left to recover for 7
days. On the day of experimentation, an internal cannula
(C315IS-4, Plastics One Inc., Roanoke, VA) was inserted through
the guide cannula and connected to a Hamilton syringe (7102KH-
2ul, Hamilton Reno., NV) with cannula tubing (C232CT, PE50/
Thin wall, Plastics One Inc., Roanoke, VA). A total volume of 1 ul
containing 50 ng of hMIC-/GDF15 or vehicle was then injected
ICV slowly over 5 minutes.
Immunofluorescence
To characterise MIC-1/GDF15 induced Fos immunoreactivity,
mice were injected IP with hMIC-1/GDF15 (0.08 mg/kg) and
anaesthetized at 30, 60 or 120 min post injection, prior to
perfusion via the ascending aorta with saline followed by ice-cold
4% paraformaldehyde (PFA). Brains were removed and postfixed
in 4% PFA at 4uC for 4 hr followed by cryoprotection in 30%
sucrose in 0.1 M phosphate buffer (PBS) at 4uC for overnight.
Coronal sections (30 mm) were cut on a sliding microtome through
the whole rostro-caudal span of the NTS from the point where the
NTS buds off from the dorsomedial edge of the spinal trigeminal
nucleus to spino-medullary junction at the level of the pyramidal
decussation (23.40 mm to 24.44 mm from interaural line) [39],
and stored in cryoprotectant (30% ethylene glycol, 20% glycerol,
50% 0.2 M PBS) until further processing. Immunofluorescent
staining was performed in all sections. After washing in 0.1 M
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PBS, sections were incubated in rabbit-anti-Fos antibody diluted at
1:10,000 in incubation buffer (0.1 M PBS containing 0.1% triton-
X100 and 2% normal donkey serum) at 4uC for 48 hr. Sections
were then washed 3 times with PBS before incubation in
DyLightTM488-donkey-anti-rabbit IgG (1:200) at room tempera-
ture (RT) for 2 hr. followed by 3 washes in PBS. The sections were
then mounted on glass slides and cover-slipped in 50% glycerol/
PBS.
For dual labeling immunofluorescence, sections were incubated
for 48 hr at 4uC in incubation buffer containing rabbit-anti-Fos at
1:10,000 and sheep-anti-tyrosine hydroxylase at 1:2000. Immu-
noreactivity was detected by incubating in DyLightTM -anti-rabbit
IgG and cy3-anti-sheep IgG (1:200) for 2 h at RT followed by 3
washes with PBS.
Ablation of the AP and NTS
Ablation of AP and NTS were undertaken by the aspiration
method [40–42]. The major advantage of aspiration lesioning is
that it is done under direct vision, which ensures accuracy.
Alternative strategies require stereotactic approaches, which are
more difficult and less reproducible. Briefly, mice were anesthe-
tized with 50 mg/kg ketamine (Pfizer, New York, NY), 25 mg/kg
xylazine (Vedco, St. Joseph, MO) and fixed on a stereotaxic
instrument (David Kopf Instruments, CA) with nose clamp and
incisor bar. The incisor bar was lowered 6.15 mm below the
interaural line to optimize AP/NTS access. A 1.5 cm longitudinal
incision was made and the dorsal neck muscles retracted to
visualize the atlanto-occipital membrane. The cisterna magna was
entered by dividing the dura. In sham-ablated mice, no further
surgery was undertaken. For AP ablation, the AP was visualized
under the dissecting microscope and lesioned by aspiration, using
a blunt 25 G needle connected to a vacuum pump drawing 10–
12 psi. For AP and NTS ablation, aspiration area was extended
bilaterally from the AP. Neck muscles were then re-apposed and
the skin closed using stainless steel clips. After surgery, mice were
given gel food (DietGel Recovery, Clear H2O, ME Portland) and
400 ml of saline subcutaneously every 12 hours for 4 days, then
daily until their weight returned to 70–80% of that measures
preoperatively. A minimum of 2–3 weeks recovery was allowed
before proceeding with experiments. Of total of 36 mice
underwent surgery, 4 died during the recovery and 32 mice
survived, and experiment was commenced when their body weight
returned to more then 85% of their preoperative weight.
Histological assessment of AP and NTS ablation and
cannula placement
Histological quantification of NTS lesioning and cannula
placement was performed in all mice at the completion of each
experiment by Nissl staining [43]. Mice were perfused with 4%
PFA and brains were fixed and cryoprotected in 20% sucrose for
overnight at 4uC. Brainstems were sectioned into 30 mm serial
coronal sections then mounted onto glass slides. After air-drying,
sections were labeled for Nissl material and the extent of the lesion
was assessed under the microscope (DMI5500, Leica) [44]. In total
of 32 mice that underwent surgery, 14 mice had complete ablation
of AP with little or no damage observed in the NTS, and 12 mice
had ablation confined to AP and medial NTS adjacent to the AP.
In most cases, the ablated regions were from where the NTS
adjoins the 4th ventricle and extended caudally to the level of
obex. Maps identify the ablated regions are shown in the results.
Of the 32 lesioned mice used for these experiments, 6 were not
included in the data analysis, as at necropsy, lesions were found to
be either too small or not confined to the region described above.
Subcutaneous osmotic pump implantation
Seven-day-osmotic minipumps (model 1007D, ALZET Osmot-
ic pump, Cupertino, CA) were loaded with vehicle or recombinant
hMIC-1/GDF15 in a concentration that delivered 1 mg/kg/day
at delivery rate of 0.5 ul/hr [19]. hMIC-1/GDF15 or vehicle-
loaded pumps were implanted subcutaneously in the interscapular
region of the AP or AP plus NTS ablated mice. Briefly, animals
were anesthetized by inhalation of isoflurane then shaved and
disinfected over the implantation site. A small incision was made
across the midline and slightly posterior to the scapula, then a
hemostat was used for blunt dissection to create a subcutaneous
space for the pump, which was inserted with the delivery portal
oriented caudally. The wound was closed with two 9 mm wound
clips.
Quantification of serum hMIC-1/GDF15 levels in mice
To determine the peak serum concentrations of hMIC-1/
GDF15, mouse blood samples were collected at 0, 15, 30, 45, 60,
90, 120 and 240 minutes after a single IP injection of 0.08 mg/kg
of hMIC-1/GDF15. To measure the steady state serum concen-
trations of hMIC-1/GDF15, blood sample were collected from
mice at day 6 of infusion of hMIC-1/GDF15 via osmotic
minipump. In both cases, blood samples were collected by cardiac
puncture and allowed to clot by standing for 2 hr at 4uC. After
centrifugation, the collected sera were stored at270uC for assay of
hMIC-1/GDF15, using a previously described in house ELISA
[2,45].
Analysis of body weight and food intake in mice
Mice were single housed and acclimated on paper-towel (Chux,
Padstow NSW Australia) bedding for 3 days prior to pump
implantation and commencement of food intake. After the pump
was implanted, body weight, food spillage on the bedding and food
in the food hopper were weighed every morning between 9:00 to
10:00 hr for 5 consecutive days. Food consumption was
determined by subtracting food left in the hopper and the spillage
collected from the bedding, from the weight of the food supplied
[16].
Since AP ablation itself leads to an increase in basal food intake
[46], weight gain and food intake for the individual ablation
groups were corrected by normalizing hMIC-1/GDF15 induced
weight and food intake change to the average weight and food
intake change from their respective vehicle treated control group.
This was done by defining the mean body weight change in the
vehicle treated arm of each group as 100%, and then scaling the
weight change in the hMIC-1/GDF15 group appropriately (5C
and 5D).
Data analysis of immunofluorescent labeling
Five animals from each treatment group were analysed for Fos
immunofluorescent staining and 3 animals from each treatment
were analysed for dual Fos and TH staining. Very few Fos
immunoreactive neuronal bodies were found in the rostral level of
NTS that extends rostrally from the junction between the AP and
the 4th ventricle to the NTS adjacent to the dorsomedial edge of
the spinal trigeminal nucleus. Similarly, only very few Fos
immunoreactive neurons were found in the caudal level of NTS
that extend caudally from obex to the spino-medullary junction at
the level of the pyramidal decussation. Therefore the immunore-
active neurons in the AP and the adjacent medial NTS were
enumerated. Images were obtained and archived using a
DMI6000B imaging microscope (Leica, Wetzlar, Germany).
Counts were corrected using the Abercrombie correction equation
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for estimating numerical neuronal densities P=A[M/(M+L)] (von
Bohlen und Halbach and Unsicker 2003; von Bohlen und
Halbach et al. 2004). In this equation P is the average number
of nuclear points per section; A is the crude counted number of
nuclei seen in the section; M is the mean thickness of the virtual
section; L is the mean length of the nuclei. In a first step, A is the
counted in the different brain nuclei. In a second step, L was
estimated for each different brain nucleus by computer-controlled
measurement of the height of the cells in the z axis using the
DMI6000B microscope.
Statistical analysis
Statistical analyses were performed using GraphPad Prism
software. A two-tailed unpaired t-test was used to assess
significance in all cases unless otherwise specified. The threshold
for statistical significance was set at p,0.05. All data are expressed
as mean 6 s.e.m.
Results
Intracerebroventricular administered hMIC-1/GDF15
induces anorexia and weight loss
To provide further data supporting MIC-1/GDF15’s direct
central actions, and to complement previous studies in which we
have induced local expression of MIC-1/GDF15 in the hypothal-
amus [16], we administered hMIC-1/GDF15 (50 ng) or vehicle
directly to the CNS, via Intracerebroventricular (ICV) injection
into the lateral ventricle, from where it flowed into the 3rd and 4th
ventricles. hMIC-1/GDF15 treated mice lost an average of
160.2 g of body weight (p=0.03, n= 6, paired t-test), while
vehicle treated mice gained average of 0.560.2 g of body weight
(p=0.11, n = 6, paired t-test) (Fig. 1A). hMIC-1/GDF15 treatment
effectively reduced the body weight in comparison to vehicle
treated animal (hMIC/GDF15 vs vehicle, p=0.05, n = 6). The
weight loss in the hMIC-1/GDF15 treated group was due to
reduced food intake as this group consumed significantly less food
then the vehicle treated group (Fig. 1B) (p=0.002, n= 6, unpaired
t-test). To verify that the effects of ICV administered hMIC-1/
GDF15 were not due to its access to the systemic circulation, a
further two groups of 6 mice each were given either a single IP
injection of vehicle or hMIC-1/GDF15 (100 ng) at double the
dose given ICV. This systemic dose had no effect on body weight
or food intake (data not shown). These data provide further strong
support for the direct action of MIC-1/GDF15 on central appetite
regulatory pathways.
Systemic hMIC-1/GDF15 induces Fos immunoreactivity in
AP, NTS, and caudal DMX
We have previously demonstrated a single IP injection of
hMIC-1/GDF15 induces Fos immunoreactivity in mouse caudal
brainstem neurons [16]. To determine the time of maximum Fos
immunoreactivity induced by hMIC-1/GDF15, we gave groups of
5 mice a single IP injection of 0.08 mg/kg of hMIC-1/GDF15 or
vehicle. Their brains were collected at 30, 60 or 120 minutes post
injection, after which we mapped Fos immunoreactivity through-
out the rostro-caudal span of the brainstem. This dose of hMIC-1/
GDF15 induced peak hMIC-1/GDF15 serum levels to an average
of 13.861.5 ng/ml (n = 8) at 30 minutes post injection. Prolonged
steady state serum levels of this magnitude, are strongly associated
with anorexia/cachexia in both mouse and man [16,18].
For both AP and NTS, maximal Fos immunoreactivity was
observed at 60 minutes after injection (Fig. 2). By contrast,
injection of vehicle resulted in virtually no Fos immunoreactivity
(Fig. 2). The distribution and density of activated neurons was
consistent among individual hMIC-1/GDF15 injected animals
(n = 5). The highest density of hMIC-1/GDF15 induced Fos
immunoreactivity was observed in the AP and the medial division
of NTS, especially in the intermediate, commissural subnuclei and
subpostrema subnuclei of the medial NTS. Only few neurons with
Fos immunoreactivity were observed at caudal level of NTS,
which extends into the medulla to the junction with the spinal
cord. Fos immunoreactivity was rarely found in the rostral NTS,
from the level of the NTS at the junction between the AP and the
4th ventricle to the point where the NTS buds off from the
dorsomedial edge of the spinal trigeminal nucleus. In the AP, the
medial-caudal portion contained a higher density of Fos immu-
noreactivity. Additionally, hMIC-1/GDF15 induced Fos immu-
noreactive neurons were also observed in the caudal division of the
dorsal motor nucleus of vagus (caudal DMX) extending from the
level of obex to the spino-medullary junction at the level of the
pyramidal decussation. No neuronal activation was seen in the
rostral part of the DMX (i.e. caudal to the AP).
MIC-1/GDF15 activates TH-positive and TH-negative
brainstem neurons
To characterize the pattern and phenotype of brainstem
neurons activated by systemic administration of hMIC-1/
GDF15, we carried out dual immunofluorescent staining for Fos
and TH at 60 minutes after a single IP injection of (0.08 mg/kg) of
hMIC-1/GDF15 (Fig. 3A, 3B, and 3C). Since hMIC-1/GDF15
predominantly activated neurons in the AP and the medial
division of the NTS, quantitative analysis of staining was
Figure 1. ICV administrated hMIC-1/GDF15 induces anorexia and weight loss. A single injection of 50 ng of hMIC-1/GDF15 or vehicle was
delivered ICV. Changes in body weight (A) and changes in food intake (B) were compared 16 hr post injection. Data expressed as mean 6 s.e.m.
Abbreviations: BW, body weight; FI, food intake.
doi:10.1371/journal.pone.0100370.g001
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performed on these sites (Fig. 3D). Consistent with previously
published reports [47], TH-positive neurons were seen within the
AP, caudal DMX, and commissural subnucleus of medial NTS in
a similar distribution to those activated by hMIC-1/GDF15
(Fig. 3B). An average of 629639 TH-positive immunoreactive
neurons and 590611 Fos-positive neurons were identified in the
AP and medial NTS of hMIC-1/GDF15 treated mice (Fig. 3E,
n = 3), of which about 10% or 6166 neurons showed colocalisa-
tion. In contrast, vehicle treated mice (n = 3) had an average of
4862 Fos-positive neurons and 500637 TH-positive neurons of
which less then 0.1% or 1.360.3 neurons were colocalised (hMIC-
1/GDF15 vs vehicle n= 3, p,0.001). As 10% of the hMIC-1/
GDF15 induced Fos immunoreactive neurons were TH-positive
and 90% were TH-negative neurons (Fig. 3D), it was clear that
catecholaminergic neurons formed a minority of hMIC-1/GDF15
activated neurons in the AP and medial NTS, with the majority
being non-catecholaminergic. In the DMX, hMIC-1/GDF15
treatment also resulted in Fos immunoreactivity in 3264 (n= 3)
neurons compared to 561 in vehicle treated animals (Fig. 3H,
n= 3; p,0.01), none of which colocalised with TH-positive
neurons.
MIC-1/GDF15-mediated reduction in body weight and
food intake is dependent on neurons in the AP and/or
NTS
To determine the relative importance of the AP and NTS in the
anorexigenic actions of disease-related concentrations of MIC-1/
GDF15, we surgically ablated these regions in mice [42].
Aspiration lesioning of the AP alone removed all recognizable
remnants of the AP, including the subpostrema in 14 mice, 6 mice
of which were infused with hMIC-1/GDF15 and 8 with vehicle.
Aspiration lesioning of the AP plus NTS was achieved in 12 mice,
7 of which were treated with hMIC-1/GDF15 and 5 with vehicle.
The remaining NTS structures included the rostral NTS nuclei
(extending rostrally from the level where NTS adjoins the 4th
ventricle), caudal NTS (extending caudally from the obex), as well
as some of the ventrolateral subnucleus of the medial NTS
(Fig. 4D). Representative sections of sham operated, AP ablated
and AP plus NTS ablated mice, labeled for Nissl material are
shown in Fig. 4A–C respectively. The lesioned area overlapped
very well with the region where hMIC-1/GDF15 induced Fos
immunoreactivity was identified (Fig. 2 and Fig. 4). After recovery,
mice were infused with vehicle or hMIC-1/GDF15 (1 mg/kg/
day), which raised its steady state serum levels to an average of
0 ng/ml and 16.360.1 ng/ml (n = 8), respectively. The latter
levels, if maintained, are strongly associated with anorexia/
cachexia in mouse and man [16,18].
Five days of hMIC-1/GDF15 infusion induced significant
weight loss in sham-operated mice, which lost an average of
160.2 g from their starting weight, while the vehicle treated
animals gained an average of 0.860.1 g (Fig. 5A; hMIC-1/
GDF15 vs vehicle; p,0.001, n= 5). Consistently, sham operated
hMIC-1/GDF15 infused mice had a significant reduction in daily
food intake compared to the vehicle treated mice (Fig. 5B; p,0.01,
n = 5). This anorectic effect of MIC-1/GDF15 was completely
abolished by AP/NTS ablation. Both vehicle treated mice and
hMIC-1/GDF15 treated mice with AP/NTS ablation gained
similar amounts of weight (respectively, an average of 1.360.1 g
and 1.12160.2 g; Fig. 5A; p=0.6, n= 7). Food intake was also
Figure 2. Systemic hMIC-1/GDF15 induces Fos immunoreactivity in brainstem nuclei. Photomicrographs represent coronal sections (2
3.5 mm from interaural line) of Fos immunoreactivity at 30, 60 or 120 min after systemic IP administration of a single dose of hMIC-1/GDF15 or
vehicle. Scale bar: 40 mm. Abbreviations: DMX, dorsal motor nucleus of vagus; ap, area postrema; cc, central canal; NTS, nucleus of the solitary tract.
doi:10.1371/journal.pone.0100370.g002
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similar in these two groups (Fig. 5B; p=0.8, n = 7). This indicated
that an intact AP and NTS are required for MIC-1/GDF15 to
exert its anorexigenic action.
By contrast, localized lesioning of the AP alone had only a small
effect on the anorexigenic actions of MIC-1/GDF15. The AP
ablated vehicle treated mice gained an average of 1.360.3 g from
their starting body weight after five days of infusion. This was
significantly different from AP ablated hMIC-1/GDF15 treated
mice that had gained an average of only 0.1460.02 g from their
starting body weight (Fig. 5A; p,0.01, n= 6). AP ablated hMIC-
1/GDF15 treated mice had significant weight gain compared to
that of sham operated hMIC-1/GDF15 treated mice (Fig. 5A; p,
0.01, n= 6), suggesting that AP ablation may have partially
inhibited the anorectic effect of hMIC-1/GDF15. However AP
ablated vehicle treated mice also ate more and gained significantly
more weight compared to that gained by sham operated vehicle
Figure 3. MIC-1/GDF15 activates both TH-positive and TH-negative neurons. Photomicrographs of coronal sections through the rostro-
caudal span of NTS, demonstrate the distribution of dual Fos (Panel A, green), and TH immunoreactivity (Panel B, red). The merged images are in
panel C, scale bar: 40 mm. (D) The Line graph shows the number of neurons that are Fos-positive or Fos and TH-positive in various AP/mNTS regions,
identified as mm distance relative to the interaural line. (E-H) The bar graphs show the number of neurons that are immunoreactive to TH, or Fos, or
both TH and Fos in mNTS, AP or DMX. Data are presented as mean6 sem. Abbreviations: DMX, dorsal motor nucleus of vagus; ap, area postrema; sp,
subpostrema; cc, central canal; NTS, nucleus of the solitary tract; mNTS, medial region of nucleus of the solitary tract.
doi:10.1371/journal.pone.0100370.g003
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treated mice (Fig. 5A and 5B p=0.02, n= 6; p,0.01, n= 6,
respectively). Consistent with previous studies in rats, our vehicle
treated AP ablated mice also displayed hyperphagia, suggesting a
modification of control of food intake by the AP [46], which could
potentially confound our comparisons between vehicle and hMIC-
1/GDF15 treated AP/NTS ablated mice. Therefore, to account
for this factor, weight gains for the individual groups were
normalised as described in the methods. After this correction, a
significant difference was found in the relative weight reduction in
sham operated hMIC-1/GDF15 treated mice to that of AP
ablated hMIC-1/GDF15 treated mice (Fig. 5C p=0.01, n = 6).
However, there was no significant change in normalised food
intake between these two groups (Fig. 5D).
A similar normalization procedure was performed for the AP/
NTS lesioned mice. hMIC-1/GDF15 infusion had no effect on
either normalised weight change (Fig. 5C) or food intake (Fig. 5D)
in this group, indicating that lesioning this area completely
prevented the anorexigenic actions of hMIC-1/GDF15. This
result differed significantly from the sham-operated control mice in
which hMIC-1/GDF15 reduced food intake and body weight as
expected (Fig. 5C–D. body weight p,0.001, n= 7; food intake p,
0.03, n= 7).
Discussion
This study reveals a key role for the brainstem in mediating the
anorexigenic actions of MIC-1/GDF15. To explore its actions in
the AP and NTS, we determined the distribution of neuronal Fos
immunoreactivity in AP and NTS at 60 min after a single IP dose
of hMIC-1/GDF15. This dose of hMIC-1/GDF15 activated
mostly non-TH neurons in the AP and medial NTS. Ablating
neurons in this region completely abolished hMIC-1/GDF15
induced effects on body weight and food intake, establishing
neurons in the AP and/or NTS as essential for the anorexigenic
actions of MIC-1/GDF15. However, exactly how MIC-1/GDF15
acts on these neurons is still unclear.
Neurons in the AP and/or NTS could directly respond to
systemic MIC-1/GDF15 by binding to and activating the MIC-1/
GDF15 receptor. While this receptor has not been identified, it is
likely to belong to the highly conserved hetero-tetrameric chains of
the TGF-b receptor (TBR) superfamily. Some data suggests that
Figure 4. AP and NTS ablation. Representative Nissl stained sections of AP and mNTS from mice who were (A) Sham operated, (B) AP ablated or
(C) AP/NTS ablated. (D) The extent of AP plus NTS lesioning is represented as shaded areas on drawings at four levels of the AP and NTS, which are
localised by mm distances from the interaural line.
doi:10.1371/journal.pone.0100370.g004
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the TBRII, may form a component of the MIC-1/GDF15
receptor [16,48], and this receptor is relatively highly expressed on
AP neurons [49]. MIC-1/GDF15 is also known to activate the Arc
and PVN, and this may occur indirectly via the activation of
hindbrain neurons that project to these hypothalamic areas [50–
52]. Alternatively, the AP/NTS might be activated via a
multisynaptic route, initiated by the direct actions of MIC-1/
GDF15 on the Arc. Finally, systemic MIC-1/GDF15 might act
independently at both locations due to its direct actions via the
fenestrated capillaries, which are a characteristic of these
circumventricular organs.
In addition to the AP and NTS, systemic injection of hMIC-1/
GDF15 also activated a small number of neurons in the caudal
DMX. The major role of DMX neurons is to transmit nerve
impulses through the vagus nerve down to the gastrointestinal
tract. These caudal DMV neurons could be activated by systemic
hMIC-1/GDF15-induced signals transmitted from the AP
[24,53]. Alternatively, they could be activated by synaptic input
from NTS that carries signals originating in the vagus and other
cranial nerves. Here MIC-1/GDF15, like CCK, might activate
the vagus nerve to reduce gastrointestinal motility.
Only a small proportion of the hMIC-1/GDF15 activated
neurons were TH-positive. This indicates that, unlike satiety
factors such as CCK and oleoylethanolamide, which are released
from the small intestine and activate NTS catecholaminergic
neurons [54,55], hMIC-1/GDF15 predominantly activated non-
catecholaminergic neurons. However, this does not exclude a
contribution of catecholaminergic neuronal activation to MIC-1/
GDF15 effects. Further studies will be required to more precisely
identify the major AP/NTS neuronal subsets, through which
MIC-1/GDF15 acts.
Complete ablation of the AP/NTS complex completely inhibits
the anorexigenic actions of MIC-1/GDF15 whilst ablation of the
AP alone results in little inhibition. This suggests that the AP is
likely to play a smaller part in MIC-1/GDF15 control of food
intake. Further studies will require cell specific deletion of the
MIC-1/GDF15 receptor but these will not be possible till it has
been identified and characterized.
In sum, this study demonstrates that neurons of the NTS are
critical for the anorectic actions of disease-associated concentra-
tions of MIC-1/GDF15, an effect that may be dominantly
mediated by activation of non-catecholaminergic neurons. It is yet
to be determined if lower concentrations of MIC-1/GDF15, closer
to its physiological levels, also act through the brainstem, or
through other regions of the brain such as the Arc and/or PVN.
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Figure 5. The effect of MIC-1/GDF15 on body weight and food intake reduction requires neurons in the AP and/or NTS. The effect of
hMIC-1/GDF15 on mice (A) body weight change and (B) food intake change following ablation of the AP or AP plus NTS or sham surgery. The effect of
MIC-1/GDF15 was normalised against the effect on vehicle treated mice for (C) changes in body weight and (D) changes in food intake. Data
expressed as mean 6 s.e.m. Abbreviations: BW, body weight; FI, food intake.
doi:10.1371/journal.pone.0100370.g005
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